Agenix to develop the Institute of Medicinal Biotechnology's AGX-1009(anti-HBV)

interdetect

Agenix, under license from the Institute of Medicinal Biotechnology (IMB) of the Chinese Academy of Medical
Sciences, is investigating prodrug analog AGX-1009, a nucleotide analog reverse transcriptase inhibitor
(NtRTI), for the potential treatment of hepatitis B virus (HBV) infection.
In September 2010, Agenix reported that AGX-1009 did not inhibit cytochrome P450 at doses above therapeutic
levels.
By September 2010, it was reported that from preliminary pharmacodynamic, pharmacokinetic and toxicity
studies performed by IMB researchers, AGX-1009 had demonstrated inhibition against HIV-1 and HBV, as well
as a low toxicity profile and high oral bioavailability.

StephenW

回复 interdetect 的帖子

Agenix - an Australian company.

interdetect

回复 StephenW 的帖子

Good, I find that Agenix invested 2.4 million $.

qdmhyneg

hatecccdna

你之前说的就是这个？

interdetect

回复 hatecccdna 的帖子

no, this is a new investigated drug in development.

lin12345

genix下，从医药生物技术研究所（IMB）的医疗中国科学院牌照
科学，正在调查药模拟卤化银- 1009，一个核苷酸类似物逆转录酶抑制剂
（NtRTI），为乙型肝炎病毒（HBV）感染的潜在治疗。
2010年9月，Agenix报道，卤化银- 1009并没有抑制治疗的剂量上述细胞色素P450
水平。
2010年9月，据报道，从初步的药效学，药代动力学和毒性
国际海事局的研究人员进行的研究，卤化银- 1009已经证明抗HIV - 1和HBV的抑制，以及
作为一种低毒性和高口服生物利用度。